https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36361 Wed 24 May 2023 12:19:20 AEST ]]> Proteins Annexin A2 and PSA in prostate cancer biopsies do not predict biochemical failure https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33534 Wed 23 Feb 2022 16:05:22 AEDT ]]> Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42275 Tue 07 Nov 2023 11:20:11 AEDT ]]> Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40388 Thu 14 Jul 2022 11:42:24 AEST ]]> Survival benefit confirmed for prostate cancers diagnosed by PSA testing (letter) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8356 Sat 24 Mar 2018 08:39:51 AEDT ]]> Gleason scoring: a comparison of classical and modified (International Society of Urological Pathology) criteria using nadir PSA as a clinical end point https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10469 Sat 24 Mar 2018 08:09:12 AEDT ]]> Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21389 Sat 24 Mar 2018 08:05:04 AEDT ]]> Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21390 p< 0.001) in urinary dysfunction were measured using the EORTC PR25 instrument at 18 and 36 months. Conclusion: Adjuvant androgen suppression, bisphosphonates and increasing EBRT dose did not increase rectal or urinary dysfunction in this trial. However dose escalation using HDRB increased urinary dysfunction.]]> Sat 24 Mar 2018 08:05:03 AEDT ]]> A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18126 Sat 24 Mar 2018 08:04:29 AEDT ]]> Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22823 Sat 24 Mar 2018 07:16:10 AEDT ]]> A randomised trial investigating the effect on biochemical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definitive radiation treatment for localised carcinoma of the prostate https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33247 7 cutpoint identified in 2014 for the BP and STI endpoints. A tertiary objective of the trial is to determine whether intercurrent medical conditions will impact independently on delayed radiotherapy morbidity and other treatment related morbidity.]]> Mon 23 Sep 2019 13:37:53 AEST ]]> Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41992 Mon 10 Jul 2023 11:24:21 AEST ]]>